舒泰神：STSP-902滴眼液I期临床研究总结报告

Core Viewpoint - The company has obtained the Phase I clinical study summary report for STSP-902 eye drops, which are intended for the treatment of neurotrophic keratitis, indicating progress in its clinical development [1] Group 1: Clinical Development - The company plans to submit the clinical trial application for STSP-902 in April 2024, with approval expected in July 2024 and the first subject dosing completed by October 2024 [1] - The study results demonstrate that both single and multiple doses of STSP-902 eye drops show good overall safety and tolerability in healthy subjects, with no systemic drug exposure or immunogenicity observed [1] - Pharmacokinetic results indicate that the trial drug can still be detected in tear samples 6 hours after a single dose administration [1] Group 2: Future Implications - The results support the initiation of further clinical trials in patients with neurotrophic keratitis, suggesting potential for future therapeutic applications [1]